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asahiko Hara, MD, Masami Nishino, MD, Masayuki Taniike, MD,
obuhiko Makino, MD, Hiroyasu Kato, MD, Yasuyuki Egami, MD, Ryu Shutta, MD,
itoshi Yamaguchi, MD, Jun Tanouchi, MD, Yoshio Yamada, MD
akai, Osaka, Japan
bjectives The purpose of this study is to compare the neointimal formational pattern and incidence of
hrombus formation among sirolimus-eluting (SES), paclitaxel-eluting (PES), and bare-metal stents (BMS)
ith coronary angioscopy.
ackground Neointimal formation and incidence of mural thrombus are different with the type of
tent.
ethods One hundred successive patients who received 43 SES, 40 PES, or 32 BMS implantation
nderwent 6-month follow-up coronary angioscopy. We evaluated angioscopic parameters, includ-
ng minimum and maximum neointimal grade; presence and number of red mural thrombus; neoin-
imal grade around thrombus; and heterogeneity score, which is deﬁned by subtracting minimum
rom maximum grade within 1 stent by classifying angioscopic neointimal coverage grades into 4
ategories. We compared these parameters among 3 kinds of stent groups.
esults Heterogeneity scores of SES, PES, and BMS were 0.79  0.60, 1.27  0.75, and 1.03  0.82,
espectively (p  0.011). The PES showed the highest incidence of angioscopic red mural thrombus
50% in PES, 12% in SES, and 3% in BMS, p  0.001), and the number of thrombus observed within
stent in the PES group tended to be larger than those in the SES and BMS groups.
onclusions At 6 months after stent implantation, PES showed the most heterogeneous neointimal
ormation and the highest incidence of thrombus formation compared with SES and BMS. (J Am
oll Cardiol Intv 2010;3:215–20) © 2010 by the American College of Cardiology Foundation
rom the Division of Cardiology, Osaka Rosai Hospital, Sakai, Osaka, Japan.anuscript received June 22, 2009; revised manuscript received October 27, 2009, accepted October 29, 2009.
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216trong evidence of benefits with first-generation drug-
luting stent (DES) compared with bare-metal stent (BMS)
oth for on- and off-label indications have led to the use of
ES in the majority of percutaneous coronary interventions
1,2). However, the risk of stent thrombosis after DES
mplantation remains a serious concern. One of the possible
echanisms for an increased risk of stent thrombosis in
ES is delayed arterial healing and high incidence of mural
hrombus, which have been revealed by several postmortem
athological studies and real-time imaging studies such as
ptical coherence tomography or coronary angioscopy
3–5). Moreover, neointimal formation is different with the
ype of DES (6,7).
The purpose of this study is to compare the neointimal
overage pattern and incidence of thrombus formation among
irolimus-eluting stent (SES), paclitaxel-eluting stent (PES),
nd cobalt alloy BMS with coronary angioscopy.
ethods
atients. The study patients consisted of 100 successive
atients who underwent single type stent implantation for
de novo lesions, with SES
(Cypher, Cordis, Miami Lakes,
Florida), PES (Taxus Express2,
Boston Scientific, Natick, Mas-
sachusetts), or BMS (Vision,
Abbott, Saint-Laurent, Canada;
and Driver, Medtronic, Santa
Rosa, California). They all ac-
cepted 6-month angiographic
follow-up with angioscopic as-
essment of the stent. We compared patient and lesion
haracteristics, late lumen loss with quantitative coronary
ngiography, and coronary angioscopic parameters among
hese 3 kinds of stent groups. Major adverse cardiac events
cardiac death, nonfatal myocardial infarction, or target
essel revascularization) were also assessed at 1 year after
oronary angioscopy.
All SES were implanted between September 2006 and
ay 2007, because SES was the only DES available in
apan during the period, and all PES were implanted
etween June 2007 and December 2007 in the same
anner. The PES was approved for clinical use from May
007 in Japan and became available in June 2007 at our
nstitution. The decision to use either a BMS or DES was
t the discretion of the attending physician, on the basis of
he relative advantages and disadvantages of each type of
tent (8). We defined late lumen loss as the difference
etween the minimum lumen diameter immediately after
tenting and that at 6-month angiographic follow-up with
uantitative coronary angiography with QAngio XA (Medis
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)edical Imaging Systems, Leiden, the Netherlands). cThe ethics committee at Osaka Rosai Hospital approved
his study, and written informed consent was obtained from
ll patients before catheterization.
ntiplatelet regimen. All patients received 100 mg aspirin
uring the follow-up period. Ticlopidine (200 mg) was
iven additionally as a dual antiplatelet regimen for at
east 3 months after stent implantation in the SES group,
or at least 6 months in the PES group, and for at least 2
eeks in the BMS group. The drug was changed to
ilostazol (200 mg) if side effects were present. Dual
ntiplatelet therapy was ceased at attending physician’s
iscretion.
ngioscopic technique and analysis. Angioscopy (Fiber
atheter, Fiber Tech, Chiba, Japan) was performed after
ollow-up coronary angiography after intravenous adminis-
ration of 5,000 U heparin. The optical fiber was manually
ulled back from the distal part of the stent to the proximal
art under careful angioscopic and angiographic guidance to
valuate as many parts of stents as possible. Angioscopic
mages were recorded on digital video discs for subsequent
nalysis.
We classified neointimal coverage grade into 4 categories.
rade 0 represents stent struts without endothelialization
howing glistening metallic luster similar to that immedi-
tely after stent implantation. Grade 1 represents stent
truts with very thin neointimal coverage and visible metallic
olor but without metallic luster. Grade 2 represents stent
truts without metallic color but not fully embedded in
eointima. Grade 3 represents invisible stent struts with full
eointimal coverage (Fig. 1). The best-covered segment was
efined as the maximum grade, the worst-covered was the
inimum grade, and heterogeneity score was defined by
ubtracting the minimum from maximum grade within 1
tent.
We also evaluated the incidence and number of red mural
hrombus and neointimal coverage grade around thrombus.
ed mural thrombus was defined as an isolated coalescent
ed superficial or protruding mass that could not be flushed
ut by dextran solution injection. Overlapping stent area
as excluded from evaluations of this study. Two indepen-
ent observers who were unaware of the clinical information
nalyzed the images.
tatistical analysis. Statistical analysis was performed with
PSS for Windows, version 11.0 (SPSS, Inc., Chicago,
llinois). We assumed that the data were approximately
ormally distributed. Continuous and ordinal variables were
resented as mean SD. We employed analysis of variance
or the evaluation of continuous variables and Kruskal-
allis test for the evaluation of ordinal variables. Post hoc
ultiple comparisons were additionally performed for as-
essing neointimal coverage grade and heterogeneity score
ith Tukey’s test or Games-Howell test after Levene’s test
or equality of variance, because a nonparametric multiple
omparison test was not available with the statistical soft-
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217are we used. Categorical variables were presented as
requencies and analyzed by the chi-square test. A p value
0.05 was considered statistically significant. We also
ssessed independent predictors for the presence of red
ural thrombus with multiple logistic regression analysis
ith all available variables as independent variables. The
nter-rater reliability for the number of mural thrombi was
valuated with intraclass correlation coefficient. The inter-
ater reliabilities for other angioscopic parameters were
ssessed with Cohen’s kappa coefficient. Cohen’s kappa
oefficient 0.80 was considered to be almost perfect
greement. When stents were the unit of analysis, no
orrection was made for correlated observations within
ndividuals.
esults
atient and lesion characteristics. Thirty-five patients un-
erwent 43 SES, 35 patients underwent 40 PES, and 30
atients underwent 32 BMS (7 Vision and 25 Driver stents)
mplantations. Patient and lesion characteristics are shown
n Table 1. There were some significant differences in these
emographic data. No signs of thrombi were revealed by
ngiography at the day of follow-up. However, 1 patient
ho received implantation with PES was admitted to the
ospital, due to late stent thrombosis approximately 2
onths after coronary angioscopy (Fig. 2).
ngioscopic ﬁndings. Angioscopic findings are shown in
igure 3 and Table 2. Heterogeneity scores of SES, PES,
nd BMS were 0.79  0.60, 1.27  0.75, and 1.03  0.82,
espectively (p  0.011). Neointimal coverage of BMS is
uch greater than that of DES, whereas heterogeneity score
as highest in PES. In addition, incidence of red mural
hrombi in PES was much higher than in SES or BMS. We
etected angioscopic red mural thrombus in 5 (12%) SES.
Figure 1. Neointimal Coverage Grade Around Red Mural Thrombus
Arrows indicate red mural thrombi next to focusing neointimal coverage grad
metallic luster similar to that immediately after stent implantation. Grade 1 rep
but without metallic luster. Grade 2 represents stent struts without metallic co
with full neointimal coverage.wo of them were undergoing dual antiplatelet therapy at theay of follow-up. We also found red mural thrombi in 20
50%) PES and 1 (3%) BMS, although all of these patients
ere undergoing dual antiplatelet therapy at the day of follow-
p. The number of thrombi and neointimal coverage grade
de 0 represents stent struts without endothelialization showing glistening
ts stent struts with very thin neointimal coverage and visible metallic color
t not fully embedded in neointima. Grade 3 represents invisible stent struts
Table 1. Patient and Lesion Characteristics
SES PES BMS p Value
Patient characteristics n  35 n  35 n  30
Age 68 8 69 8 66 11 0.284
Male 27 (77) 32 (91) 28 (93) 0.096
Major coronary risk factors
Hypertension 27 (77) 31 (89) 25 (83) 0.444
Diabetes mellitus 12 (34) 12 (34) 6 (20) 0.360
Smoking 18 (51) 22 (63) 17 (57) 0.627
Dyslipidemia 32 (91) 31 (89) 29 (97) 0.481
Serum markers
Hemoglobin A1c (%) 5.8 0.9 5.8 1.1 5.5 0.6 0.168
LDL cholesterol (mg/dl) 112 25 104 27 89 24 0.002
HDL cholesterol (mg/dl) 48 11 47 10 43 11 0.175
hs-CRP (mg/dl) 0.21 0.35 0.22 0.41 0.22 0.33 0.988
e-GFR (ml/min/1.73 m2) 91 22 86 23 93 25 0.519
MACE at 1 year after
angioscopy
0 (0) 1 (3) 0 (0) 0.391
Lesion characteristics n  43 n  40 n  32
Follow-up period (days) 199 32 190 20 193 20 0.355
ACS 9 (21) 1 (3) 23 (72) 0.001
Stent diameter (mm) 3.0 0.4 3.1 0.3 3.5 0.4 0.001
Stent length (mm) 25.1 5.8 24.6 6.6 19.0 4.9 0.001
Late lumen loss (mm) 0.11 0.11 0.36 0.26 0.93 0.28 0.001
Dual antiplatelet therapy at
the day of angioscopy
23 (54) 40 (100) 9 (28) 0.001
Data are presented as mean SD or n (%).
ACS  acute coronary syndrome; BMS  bare-metal stent(s); e-GFR  estimated glomerular
filtration rate; HDL high-density lipoprotein; hs-CRP high sensitive C-reactive protein; LDL
low-density lipoprotein; MACEmajor adverse cardiac events; PES paclitaxel-eluting stent(s);e. Gra
resen
lor buSES sirolimus-eluting stent(s).
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218round thrombi demonstrated in these 26 stents were shown in
able 2. The number of thrombi in the PES group tended to
e larger than those in the SES and BMS groups. In addition,
ed mural thrombi were revealed along stent struts with even
rade 3 neointimal coverage in the PES group. Intraclass
orrelation coefficient for the number of mural thrombus was
.97. Cohen’s kappa coefficients for the evaluation of inter-
Figure 2. Case of Late Stent Thrombosis
A 62-year-old man who received implantation of a 3.0  32 mm paclitaxel-elu
6-month follow-up (A to D), coronary angioscopy showed grade 1 to 2 neoint
The patient discontinued ticlopidine immediately after the discharge. At 2 mon
due to nonfatal myocardial infarction (E). Emergent percutaneous coronary int
angioplasty (F). Pathological evaluation of aspiration substrate caused us to re
SES PES BMS SES
Minimum Grade Maxim
1.07±0.46
1.13±0.65
1.84±0.88
1.86±0.64
2.4
p = 0.001p = 0.897 p = 0.001
p < 0.001 p <
4
3
2
1
3
2
1
Figure 3. Comparison of Angioscopic Parameters
Data are presented as mean  SD and analyzed by Kruskal-Wallis test with post-h
sirolimus-eluting stent(s).ater reliability were 0.95, 0.90, 0.86, and 0.95 for minimum
rade, maximum grade, heterogeneity score, and presence of
ed mural thrombi, respectively.
redictors for red mural thrombus. Multiple logistic regres-
ion analysis revealed the relationship between the presence
f red mural thrombus and non-PES, minimum neointimal
overage grade, and estimated glomerular filtration rate with
tent in the middle portion of the left anterior descending coronary artery. At
overage at the whole stent (B to D) with multiple red mural thrombi (*).
fter angioscopy and cessation of ticlopidine, he was admitted to the hospital
ion was successfully performed with thrombectomy followed by balloon
e diagnosis of late stent thrombosis.
BMS SES PES BMS
rade Heterogeneity Score
1
2.88±0.34
0.79±0.60
1.27±0.75
1.03±0.82
p = 0.008 p = 0.330
p = 0.329
 = 0.001
1
3
2
1
mparison. BMS  bare-metal stent(s); PES  paclitaxel-eluting stent(s); SES ting s
imal c
ths a
erventPES
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219djusted odds ratio (95% confidence interval) of 0.039
0.009 to 0.176, p  0.001), 0.088 (0.021 to 0.361, p 
.001), and 1.035 (1.007 to 1.063, p  0.015), respectively.
iscussion
n the present study, we found that the minimum and
aximum neointimal coverage grades of BMS were higher
han those of SES. We also found that heterogeneity score
f PES is higher than that of SES. Incidence of red mural
hrombus of BMS was lower than that of SES, and that of
ES was higher than SES. These findings were consistent
ith the previous clinical studies (5,6). Besides, we also
evealed the differences in angioscopic parameters between
ES and BMS, and the number of thrombi observed within
stent in the PES group tended to be larger than those in
ES and BMS.
eointimal coverage pattern and incidence of thrombus
ormation. We demonstrated that the incidence of
hrombus formation of PES is much higher than that of
ES and BMS. Because there is strong correlation
etween uncovered stent struts and thrombus formation
3,4), this difference of incidence of thrombus formation
etween SES and PES is difficult to understand, because
here were no significant differences in minimum grade
etween SES and PES in this study. There are 3 possible
echanisms of this phenomenon. First, heterogeneity of
ES might have led to a higher incidence of stent struts
ithout endothelialization and resulted in the high inci-
ence of thrombus formation of PES. In other words,
ecause red mural thrombi covered stent struts without
ndothelialization next to struts with neointimal cover-
ge, we found red mural thrombi along stent struts with
ven grade 3 neointimal coverage. Second, there is a
ossibility of neointimal dysfunction for preventing
hrombus formation (9,10), even though there are no
athological supporting data that demonstrate supra-
eointimal thrombus formation so far. The neointimal
unction of SES for preventing thrombus formation
ight be superior to that of PES at 6 months after stent
mplantation. Finally, high incidence of thrombus forma-
ion might be one of the healing processes after stent
Table 2. The Presence of Thrombus
SES (n  43)
Incidence of thrombus 5 (12)
Total thrombi 10
Thrombi/stent 2.0 1.0
Neointimal coverage grade around thrombi
Grade 0/1/2/3 4 (40)/2 (20)/4 (40)/0 (0)
Data are presented as n (%), n, or mean SD
Abbreviations as in Table 1.mplantation. We demonstrated a red mural thrombus olong stent struts with even grade 3 neointimal coverage,
nd this thrombus looked whitish (Fig. 1), which made
s imagine the red mural thrombus might be covered
ith neointima.
At any rate, because many of our study patients did not
how any evidence of thrombotic events during the 18-
onth follow-up period and many large clinical trials and
egistries have not shown a significant difference in the
ncidence of clinical stent thromboses between SES and
ES (11–14), we speculated that most of these angioscopic
ed mural thrombi are subclinical. The clinical impact of
hese differences in neointimal heterogeneous property and
ncidence of thrombus formation at 6 months after DES
mplantation is low, at least under the treatment of dual
ntiplatelet therapy.
tudy limitations. There are several limitations in this study.
irst, this is a nonrandomized observational study and has a
mall number of patients. Second, although the inter-rater
eliability of the study was considered to be almost perfect
y statistical analysis, the coronary angioscopic evaluation is
ubjective with limited viewing field. In addition, the
efinition of heterogeneity score, which was calculated by
imply subtracting minimum from maximum grade, has the
ossibility to overestimate the value in cases when a single
trut was heavily covered but the rest of the stent uncovered
r in case a single strut was uncovered but the rest of the
tent was heavily covered, although we did not experience
hat situation in this study. Third, patient and lesion
haracteristics were different in some parameters, partly
ecause the decision regarding which stent (DES vs. BMS)
o place was left to the operator. This could lead to biased
esults and reminds us to interpret the data with caution.
inally, the relationship between angioscopic neointimal
overage and pathological endothelialization was not
alidated.
onclusions
t 6 months after stent implantation, PES showed the most
eterogeneous neointimal formation and the highest incidence
PES (n  40) BMS (n  32) p Value
20 (50) 1 (3) 0.001
148 1
7.4 8.2 1.0 0.296
8 (5)/26 (18)/111 (75)/3 (2) 1 (100)/0 (0)/0 (0)/0 (0)f thrombus formation compared with SES and BMS.
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